The size of a breast cancer at diagnosis has conventionally been thought of as a
fundamental and critical determinant of clinical outcome. However, the tendency of some …

Trastuzumab has revolutionised the treatment of HER2-positive early-stage breast cancer
and is now standard of care in combination with chemotherapy for patients with tumours …

Минимальный вред для здоровья обследуемой. Простота эксплуатации и содержания
оборудования. Скрининг не следует смешивать с диагностикой. Мам мография …

We investigated the association between the risk of locoregional recurrence (LRR) and
biological subtypes defined by hormonal receptors (HR) and HER-2 status in women with …

Since the introduction of anti-Her2 agents, the prognosis of HER2 positive breast cancer
patients significantly improved. In the adjuvant setting, the monoclonal antibody trastuzumab …

Accurate classification is fundamental for breast cancer (BC) personalized care. Current BC
classification based on the either traditional morphological staging or molecular signatures …

Lapatinib is an oral dual erbB 1/2 tyrosine kinase inhibitor that inhibits human EGF receptor
2 (HER2) and blocks the EGF receptor. Studies have shown that in patients with metastatic …

Background: This study assessed the impact of human epidermal growth factor receptor 2
(HER2) status on the outcomes in an unselected population of breast cancer patients who …

TO THE EDITOR: The incidence of small (T1a or T1b) breast cancers has been on the
increase during the last 15 years as a result of national screening programs. 1 Recently …

Long-term outcomes and hence the role of adjuvant therapy in patients with small (≤ 1 cm),
node-negative breast cancer remain unclear. This study's objective was to evaluate whether …